Haloperidol Richter

Haloperidol Richter is a prescription intramuscular injection containing the active ingredient haloperidol, a typical antipsychotic of the butyrophenone class. It is marketed in the European Union throughout and is supplied as a sterile solution for intramuscular use. The product is intended for healthcare professionals to manage acute psychiatric conditions requiring rapid onset of action, and it is available only with a prescription for clinical practice.

Haloperidol Richter is employed in hospital or emergency‑room environments when a fast‑acting antipsychotic is needed to stabilize patients.

- Schizophrenia, including acute exacerbations, when rapid symptom control is required. - Acute psychosis of any cause that needs intramuscular antipsychotic treatment. - Severe agitation or aggression in psychiatric patients where safety is a concern. - Manic episodes in bipolar disorder that demand immediate calming. - Behavioral disturbances in dementia (off‑label) when non‑pharmacologic strategies have failed.

Side effects of Haloperidol Richter reflect its dopamine‑blocking activity and can vary in frequency and severity.

Common: - Extrapyramidal symptoms such as tremor, muscle rigidity, or akathisia, often appearing within days of treatment. - Drowsiness, sedation, or feeling unusually sleepy, which may affect coordination. - Dry mouth, blurred vision, and mild constipation due to anticholinergic effects. - Gastrointestinal discomfort, nausea, or loss of appetite that are generally transient.

Serious: - Neuroleptic malignant syndrome, a rare but potentially fatal condition characterized by high fever, muscle rigidity, and autonomic instability. - Tardive dyskinesia, a potentially irreversible movement disorder that may develop after long‑term use. - Cardiac arrhythmias, including QT interval prolongation, which can increase the risk of serious heart rhythm disturbances.

When prescribing Haloperidol Richter, clinicians should consider several precautions to minimize risks and ensure appropriate use.

- Assess patient history for cardiovascular disease, especially conditions that predispose to QT prolongation. - Monitor for signs of extrapyramidal reactions, particularly in young adults and the elderly. - Use the lowest effective dose and limit duration to reduce the risk of tardive dyskinesia. - Evaluate liver and renal function, as impairment may affect drug clearance. - Avoid use in patients with known hypersensitivity to haloperidol or other butyrophenones. - Consider pregnancy and lactation status; the safety profile is not well established. - Review concomitant medications that may increase sedation or cardiac risk.

Haloperidol Richter can interact with other medicines, altering its effectiveness or increasing adverse effects.

Avoid: - Other dopamine antagonists or high‑potency antipsychotics, which may exacerbate extrapyramidal symptoms. - Drugs that significantly prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that can raise haloperidol plasma levels. - CYP2D6 substrates with narrow therapeutic index (e.g., metoprolol) that may have altered metabolism.

Use with caution: - CNS depressants, including benzodiazepines, opioids, or alcohol, which can increase sedation. - Antihypertensive agents, as haloperidol may cause orthostatic hypotension. - Anticholinergic medications, which may mask early signs of extrapyramidal side effects. - Lithium, as combined use may increase neurotoxic risk. - Anticholinergic medications, which may mask early signs of extrapyramidal side effects.